August 13, 2008

$9 Price Target on Anesiva

Zacks is out with an article on Anesiva, where they give the stock a $9 price target citing that the stock is relatively unknown and undervalued. This is due to the fact that their first product, Zingo has launched and that another product, Adlea is in Phase III trials.

No comments: